Technical Data
0004-01M
4-1BB Ligand (TNFSF9, CD137, CDw137, ILA, MGC2172, T-cell antigen 4-1BB homolog, T-cell antigen ILA, Tumor necrosis factor receptor superfamily member 9 precursor) (PE)
Description:
4-1BB ligand (4-1BBL; also CD137L) is a 32kD type II transmembrane protein that belongs to TNF superfamily (TNFSF) of molecules. 1-4 The human 4-1BBL cDNA encodes a 254aa protein that contains a 25aa N-terminal cytoplasmic domain, a 23aa transmembrane segment, and a 206aa C-terminal extracellular region. 5 The extracellular domain (ECD) of 4-1BBL has a jelly-roll, beta-sandwich tertiary structure that is similar to other TNFSF members. There is only one cysteine in the human ECD, and no potential N-linked glycosylation sites. The potential exists, however, for O-linked glycosylation. The human 4-1BBL ECD shares 32% and 35% aa identity with mouse and rat ECD, respectively. In the cytoplasmic domain, human 4-1BBL
is 55aa shorter than the equivalent region in rodents. 4-1BBL is expressed by activated B cells, macrophages, dendritic cells, activated T cells, neurons, and astrocytes. 2, 3, 6 A 26kD soluble form of 4-1BBL is known to occur in human. Although it is presumably generated by MMP activity, its amino acid size is currently unreported. 4 The soluble form is bioactive. Human
4-1BBL signals through both CD137/4-1BB and itself. Its cytoplasmic tail participates in reverse signaling that induces apoptosis in T cells and cytokkine secretion (IL-6; TNF-alpha) by monocytes. 7, 8 4-1BBL binding to CD137/4-1BB produces a number of effects.
It seems to play a key role in the T cell recall response. It maintains T cell numbers at the end of a primary response, and induces CD4 + and CD8 + T cells to proliferate and secrete cytokines such as IL-2 and IFN- in CD4 + cells, and IFN- in CD84-1BB Ligand/TNFSF9.

Applications:
Suitable for use in Flow Cytometry. Other applications not tested.
Optimal dilutions to be determined by the researcher.

Recommended Dilution:
Flow Cytometry: Designed to quantitatively determine the percentage of cells bearing 4-1BB Ligand/TNFSF9 within a population and qualitatively determine the density of 4-1BB Ligand/TNFSF9 on cell surfaces by flow cytometry. Washed cells are incubated with the phycoerythrin-labeled monoclonal antibody, which binds to cells expressing 4-1BB Ligand/TNFSF9. Unbound phycoerythrin-conjugated antibody is then washed from the cells. Cells expressing 4-1BB Ligand/TNFSF9 are fluorescently stained, with the intensity of staining directly proportional to the density of expression of 4-1BB Ligand/TNFSF9. Cell surface expression of 4-1BB Ligand/TNFSF9 is determined by flow cytometric analysis using 488nm wavelength laser excitation and monitoring emitted fluorescence with a detector optimized to
collect peak emissions at 565-605nm.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG2b9H4Purified
SizeStorageShippingSourceHost
100Tests-20CBlue IceHumanMouse
Concentration:
~50ug/ml
Immunogen:
Synthetic peptide corresponding to human 4-1BB Ligand /TNFSF9- Phycoerythrin.
Purity:
Purified
Form
Supplied as a liquid in 50ug antibody in 1ml PBS, 0.1% sodium azide.
Specificity:
Recognizes human 4-1BB Ligand /TNFSF9- Phycoerythrin.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Kwon, B. et al., 2003, Exp. Mol. Med. 35:8. 2. Salih, H.R. et al., 2002, Int. J. Clin. Pharmacol. Ther. 40:348. 3. Vinay, D.S. and B.S. Kwon, 1998, Semin. Immunol. 1:481. 4. Salih, H.R. et al., 2001, J. Immunol. 167:4059. 5. Alderson, M.R. et al., 1994, Eur. J. Immunol. 24:2219. 6. Reali, C. et al., 2003, J. Neurosci. Res. 74:67. 7. Michel, J. et al., 1999, Immunology 98:42. 8. Langstein, J. et al., 1998, J. Immunol. 160:2488. 9. Wen, T. et al., 2002, J. Immunol. 168:4897. 10. Dawicki, W. and T.H. Watts, 2004, Eur. J. Immunol. 34:743.